Clinical Trial Update: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating the combination of pembrolizumab with TGR-1202 (umbralisib) in relapsed/refractory chronic lymphocytic leukemia and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TGR-1202 (umbralisib)

Snippet

Sponsor: University of Chicago | Conditions: CLL, B-cell Non Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING